Doug Danison | VP, Access Value and Evidence Strategy
bluebird bio

Doug Danison, VP, Access Value and Evidence Strategy, bluebird bio

Doug has more than 18 years of Pricing & Market Access experience including roles with Eli Lilly & Company, AMGEN, Millennium/Takeda Oncology and now bluebird bio. In that time, he has led or overseen the preparation of market access strategies for products in early development, pivotal study planning, launch, and post launch lifecycle management. He?s addressed market access challenges from a variety of vantage points including Global, European Regional, and US roles. He?s built teams, processes, and a knowledgebase to help firms execute market access strategies that anticipate and meet the needs of access decision makers. Doug joined bluebird bio in July 2015 to establish the global pricing, market access, and health economics team known as Access Value & Evidence Strategy (AVES). He leads bluebird?s pricing, market access and value demonstration efforts including oversight of the Global, US, and European teams.


Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 13:00

Keynote panel discussion: Finding the right framework for reimbursement and market access for cell and gene therapies

·Europe vs USA vs ROW?·Reimbursement strategies·What’s driving the decision makers at country and national level?
last published: 10/May/21 08:45 GMT

back to speakers